Key result
High-sensitivity troponin HEART pathway linked to ~1-point higher 30-day AMI detection vs conventional pathway.
Why the study?
A new HEART pathway incorporating high-sensitivity troponin may improve cardiac risk stratification, health outcomes, and resource use compared with conventional troponin in emergency department patients with chest pain.
Does cardiac risk stratification using a HEART pathway incorporating high-sensitivity troponin improve acute myocardial infarction detection and reduce health care resource use compared with a conventional troponin HEART pathway in adult emergency department patients presenting with chest pain?
Cohort (n=17,384)
Yes
Does cardiac risk stratification using a HEART pathway incorporating high-sensitivity troponin improve acute myocardial infarction detection and reduce health care resource use compared with a conventional troponin HEART pathway in adult emergency department patients presenting with chest pain?
Implementing a high-sensitivity troponin HEART pathway in the emergency department improved early detection of acute myocardial infarction during the initial visit while reducing subsequent 30-day AMI diagnoses, hospital admissions, stress testing, and coronary revascularizations.
High-sensitivity troponin HEART pathway was associated with higher AMI detection and fewer admissions; leaves open practice change pending randomized trials.
Importance: Patients presenting to the emergency department with chest pain are routinely risk stratified for major adverse cardiac events using the HEART (History, Electrocardiogram, Age, Risk factors, and Troponin) score pathway, which incorporates clinical features, risk factors, electrocardiography findings, and initial serum troponin testing. A new HEART pathway incorporating high-sensitivity troponin level may improve risk stratification among patients with possible acute myocardial infarction (AMI). Objective: To compare health outcomes and resource use among emergency department patients undergoing cardiac risk stratification with a HEART pathway using conventional vs high-sensitivity serum troponin. Design, Setting, and Participants: This multicenter pre-post cohort study was conducted between January 1 and September 6, 2021, at 16 Kaiser Permanente Southern California hospitals during uptake of a high-sensitivity serum troponin assay and included 17 384 adult patients who presented to an emergency department with chest pain and were risk stratified with a HEART pathway based on conventional troponin or high-sensitivity troponin. Exposures: A HEART pathway incorporating either conventional or high-sensitivity serum troponin was used to stratify study groups for risk of major adverse cardiac events within 30 days. Main Outcomes and Measures: The primary outcome was detection of AMI in the emergency department and within 30 days. Results: Of the 17 384 patients (median age, 58 years [IQR, 45-69 years]; 9767 women [56.2%]), 12 440 (71.6%) were risk stratified with a HEART pathway based on conventional troponin, and 4944 (28.4%) were risk stratified with a HEART pathway based on high-sensitivity troponin. Detection of AMI within 30 days was higher for the high-sensitivity troponin group than the conventional troponin group (288 [5.8%] vs 545 [4.4%]; P < .001), while the 30-day all-cause mortality rate was unchanged (16 [0.3%] vs 50 [0.4%]; P = .50). In the emergency department, 228 of 4944 patients (4.6%) in the high-sensitivity troponin group received a diagnosis of AMI compared with 251 of 12 440 patients (2.0%) in the conventional troponin group (P < .001). Among those who did not receive a diagnosis of AMI in the emergency department, an additional 60 patients (1.2%) in the high-sensitivity troponin group and 294 (2.4%) in the conventional troponin group (P < .001) received a diagnosis within 30 days. Patients in the high-sensitivity troponin group had lower rates of health care use compared with the conventional troponin group, including admission (605 [12.2%] vs 1862 [15.0%]; P < .001), stress testing within 7 days (506 [10.2%] vs 1591 [12.8%]; P < .001), and coronary revascularization within 30 days (51 [1.0%] vs 244 [2.0%]; P < .001). Conclusions and Relevance: This multicenter pre-post cohort study suggests that a new HEART pathway incorporating high-sensitivity troponin may improve detection of AMI and decrease resource use among emergency department patients with chest pain.
No takes yet. Share an insight, caveat, or question.
Yore et al. (2023) conducted a cohort in Emergency department presentation with chest pain and suspected acute myocardial infarction (n=17,384). HEART pathway incorporating high-sensitivity serum troponin (Access hsTnI assay) vs. HEART pathway incorporating conventional serum troponin (AccuTnI+3 assay) was evaluated on Detection of acute myocardial infarction (AMI) within 30 days (including during the index ED visit) (p=<0.001). The high-sensitivity troponin HEART pathway increased 30-day acute myocardial infarction detection compared to the conventional troponin pathway (5.8% vs 4.4%, P<0.001) while reducing admissions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: